Guillermo Amescua, MD
Ophthalmology · Miami, FLNPI 1376734095
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,815 of the $54,457 with a category attached, or 73.1%. 22 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 56.9% of the total. 2025 is the largest year on record at $23,963, more than ten times the $221 reported in 2019. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $518.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$31K
- Bausch & Lomb Americas Inc.$8K
- Oyster Point Pharma, Inc.$5K
- Carl Zeiss Meditec, Inc.$4K
- Dompe Farmaceutici S.p.a.$4K
- Biotissue Holdings Inc.$423
- plus $2K from 16 others
Across 16 payments — averaging $56,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Vision Care, Inc.$908K
What the payments were for
- Consulting fees$39,81573%
- Speaking & faculty fees$8,72516%
- Travel & lodging$1,0372%
- Food & beverage$4,8809%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 26 | $31,010 |
| Bausch & Lomb Americas Inc. | 21 | $8,106 |
| Oyster Point Pharma, Inc. | 2 | $4,537 |
| Carl Zeiss Meditec, Inc. | 2 | $4,400 |
| Dompe Farmaceutici S.p.a. | 2 | $3,752 |
| Biotissue Holdings Inc. | 11 | $423 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $364 |
| Carl Zeiss Meditec USA, Inc. | 3 | $338 |
| Mallinckrodt Hospital Products Inc. | 12 | $311 |
| Alcon | 3 | $301 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $201 |
| Novartis | 2 | $146 |
| Rxsight Inc | 1 | $128 |
| Dompe US, Inc. | 1 | $111 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $110 |
| Sun Pharmaceutical Industries Inc. | 5 | $85 |
| Tarsus Pharmaceuticals, Inc. | 1 | $28 |
| Baudax Bio Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $23 |
| Santen Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Product in Development$30,814
- enVista MX60 IOL$13,374
- enVista Aspire IOL$6,551
- VisuMax$3,200
- ATLAS 500$3,200
- CALLISTO eye$3,200
- CIRRUS HD-OCT$1,200
- STELLARIS$563
- XIIDRA$258
- Prokera$232
- AmnioGraft$232
- MIEBO$150
- AcrySof IQ PanOptix$150
- TYRVAYA$142
- IC-8 Apthera IOL$138
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$128
- Tecnis Simplicity$123
- ORA$121
- Oxervate$111
How this compares
$54,457 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 626 | $30,020 |
| RestasisCyclosporine | 34 | $25,873 |
| Restasis MultidoseCyclosporine | 25 | $16,313 |
| Ketorolac Tromethamine | 228 | $5,095 |
| Loteprednol Etabonate | 14 | $4,016 |
| Fluorometholone | 49 | $3,265 |
| ValacyclovirValacyclovir Hcl | 57 | $2,968 |
| Mycophenolate Mofetil | 24 | $2,929 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 300 | $2,597 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,592 |
| MoxifloxacinMoxifloxacin Hcl | 78 | $2,416 |
| Brimonidine Tartrate | 50 | $1,776 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 72 | $628 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 42 | $544 |
| Dorzolamide Hcl | 15 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $201 | $4,01614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Miami
- William TrattlerMiami$579K
- Jennifer LohMiami$545K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$349K
- Jaclyn KovachMiami$333K
- Andrew SchimelMiami$320K
- Carlos BuznegoMiami$287K
- Felipe MedeirosMiami$266K
- Michael YimMiami$161K
- Arnulfo MansurMiami$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.